Simulations Plus today announced it has released Version 8.0 of GastroPlus, its flagship simulation software. GastroPlus 8.0 features significantly enhanced functionality and user convenience, representing a substantial upgrade of the company’s industry-leading drug absorption, pharmacokinetics, and pharmacodynamics simulation software.
Among the features of GastroPlus 8.0 is the ability to simulate both inhibition and induction of transporters and enzymes in any tissue, as well as the ability to specify dissolution rates as function of pH, including fitting “Z Factor” from multiple in vitro dissolution experiments at different pH. GastroPlus 8.0 also enables enhanced modeling of drug absorption and distribution for ocular and pulmonary delivery, and the system features the addition of a paracellular permeability model that specifically accounts for drug movement between the epithelial cells lining the intestinal wall and transport into and through cells. The software comes equipped with an enhanced PDPlus module for building pharmacodynamics models and predicting pharmacodynamics effects for new doses and dosage forms, and it also features an expanded library of animal physiologies and expanded outputs for the Population Simulator. An increased execution speed and a number of user-convenience features and “sanity checks” round out the enhanced GastroPlus 8.0 software.
GastroPlus 7.0 was released in August 2010. The updated 8.0 version represents a combination of features requested by industry scientists as well as Simulations Plus’ own design. GastroPlus is utilized by the world’s top 20 pharmaceutical companies as well as many small and medium-sized companies across the globe.
Headquartered in California, Simulations Plus is a leading developer of pioneering drug discovery and development simulation and modeling software, which is licensed and used for conducting drug research by major pharmaceutical, biotechnology, chemical, and food processing companies around the world. For more information, visit www.simulations-plus.com
Let us hear your thoughts below:
